December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

6.370 -0.070 (-1.09%)
Streaming Delayed Price Updated: 11:12 AM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Bio Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? ↗
Tevogen Bio Holdings shares are ripping higher in Monday's after-hours session after the company reaffirmed its oncology pipeline revenue forecast. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces 2025 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.